Bortezomib-induced rhabdomyolysis in multiple myeloma

Acta Haematologica

Volumn 116, Issue 3, 2006, Pages 203-206

  Cibeira, M Teresa ^a   Mercadal, Santiago ^a   Arenillas, Leonor ^a   Muntañola, Anna ^a   Salamero, Olga ^a   Bladé, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bortezomib; Multiple myeloma; Rhabdomyolysis

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LOW DENSITY LIPOPROTEIN; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; DRUG ACTIVITY; DRUG TARGETING; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; LIPOPROTEIN BLOOD LEVEL; MALE; MICROENVIRONMENT; MULTIPLE MYELOMA; MYALGIA; MYELOMA CELL; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; THROMBOCYTOPENIA;

BORONIC ACIDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; RHABDOMYOLYSIS; SALVAGE THERAPY;

EID: 33745782835     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094682     Document Type: Article

References (18)

1. Bladé J, Vesole DH, Gertz MA: Transplantation for multiple myeloma: who, when, how often? Blood 2003;102:3469-3477.
2. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Clin Cancer Res 2001;61:3071-3076.
3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Hideshima T, Esseltine DL, Anderson KC: Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional follow-up. Hematol J 2004;5(suppl 2):S103-S104.
5. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Blade J, Boccadoro M, Cavenagh J, Dalton W, Boral A, Schenkein D, Anderson K: Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. http://www.abstracts2view. com/ hem_sandiego2004/2004;104:abstract 336.5.
7. Jagannath S, Durie B, Wolf JL, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Crowley J, Schenkein D: A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. Blood 2004;104:98a-99a.
8. Berenson JR, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, Srkalovic G, Richardson PG, Esseltine DL, Anderson KC: The safety of prolonged therapy with the proteasome inhibitor bortezomib (Velcade) in relapsed and/or refractory multiple myeloma (MM). Hematol J 2004;5(suppl 2):S129.
9. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
10. Richardson P, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski R, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, Anderson KC: Peripheral neuropathy following bortezomib (Velcade, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 2003;102:149a.
11. Terpos E, Politou M, Rahemtulla A: Tumour lysis syndrome in multiple myeloma after bortezomib (Velcade) administration. J Cancer Res Clin Oncol 2004;130:623-625.
12. Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, Boral AL, Esseltine DL, Sezer O: Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003;102:386b.
13. Rosiñol L, Montoto S, Cibeira MT, Bladé J: Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005;165:464-465.
14. Warren JD, Blumbergs PG, Thompson PD: Rhabdomyolysis: a review. Muscle Nerve 2002;25:332-347.
15. Allison RC, Bedsole DL: The other medical causes of rhabdomyolysis. Am J Med Sci 2003;326:79-88.
16. Sauret JM, Marinides G, Wang GK: Rhabdomyolysis. Am Fam Physician 2002;65:907-912.
17. Visweswaran P, Guntupalli LJ: Rhabdomyolysis. Crit Care Clin 1999;15:415-428.
18. Ward MM: Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988;148:1553-1557.